vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. vTv Therapeutics' type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. The Company has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Type | Public | |
Founded | 1998 | |
HQ | High Point, NC, US | Map |
Website | vtvtherapeutics.com |
USD | |
---|---|
Revenue (Q3, 2020) | 7.0k |
Net income (Q3, 2020) | (2.3m) |
EBIT (Q3, 2020) | (2.8m) |
Market capitalization (15-Jan-2021) | 158.3m |
Closing stock price (15-Jan-2021) | 2.1 |
Cash (30-Sept-2020) | 1.8m |
EV | 159.7m |
USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 110.0k | 133.0k | 376.0k | 182.0k | 38.0k | 30.0k | 13.0k | 15.0k | 2.1m | 2.5m | 3.4m | 921.0k | 1.8m | 8.0k | 8.0k | 7.0k | |
General and administrative expense | 2.3m | 2.4m | 2.6m | 2.7m | 2.4m | 2.8m | 3.0m | 2.6m | 2.3m | 2.7m | 2.2m | 2.4m | 2.4m | 1.8m | 2.5m | 1.7m | 1.1m |
R&D expense | 5.1m | 6.6m | 11.1m | 12.1m | 10.6m | 11.0m | 9.6m | 9.0m | 8.9m | 8.6m | 2.7m | 2.8m | 4.2m | 3.7m | 4.2m | 2.5m | 1.8m |
Operating expense total | 7.4m | 9.0m | 13.7m | 14.7m | 13.0m | 13.8m | 12.6m | 11.6m | 11.2m | 11.3m | 4.9m | 5.2m | 6.6m | 5.4m | 6.7m | 4.2m | 2.8m |
USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 97.0m | 75.5m | 63.8m | 51.1m | 45.2m | 32.5m | 20.5m | 6.5m | 1.2m | 3.8m | 5.0m | 1.5m | 2.4m | 406.0k | 6.4m | 1.8m | |
Accounts Receivable | 206.0k | 210.0k | 2.3m | 1.8m | 10.0k | 5.0k | 14.0k | ||||||||||
Prepaid Expenses | 799.0k | 1.3m | 423.0k | 1.1m | 782.0k | 639.0k | 725.0k | 471.0k | 264.0k | 1.0m | 419.0k | 145.0k | 870.0k | 591.0k | 299.0k | 1.3m | |
Current Assets | 97.8m | 77.1m | 64.3m | 52.1m | 45.9m | 33.2m | 21.5m | 9.5m | 6.0m | 5.9m | 5.4m | 3.8m | 3.6m | 3.5m | 6.8m | 3.7m |
USD | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (30.0m) | (13.5m) | (28.1m) | (41.6m) | (14.3m) | (27.7m) | (40.1m) | (10.0m) | (19.6m) | (21.5m) | (4.0m) | (9.1m) | (15.1m) | (7.2m) | (12.2m) | (14.4m) |
Depreciation and Amortization | 361.0k | 79.0k | 148.0k | 216.0k | 52.0k | 104.0k | 152.0k | 42.0k | 81.0k | 111.0k | 8.0k | 16.0k | 24.0k | 27.0k | 49.0k | 72.0k |
Accounts Payable | 1.5m | 1.3m | 2.9m | 3.4m | (308.0k) | (679.0k) | (1.3m) | (2.6m) | (757.0k) | (4.9m) | (1.4m) | 635.0k | (788.0k) | 331.0k | (384.0k) | (1.4m) |
Cash From Operating Activities | (28.0m) | (12.5m) | (24.1m) | (36.8m) | (13.8m) | (26.5m) | (38.5m) | (5.4m) | (14.7m) | (21.0m) | (5.4m) | (10.9m) | (17.1m) | (5.6m) | (10.4m) | (15.8m) |
FY, 2016 | |
---|---|
Phase I Trials Products | 2 |
Phase II Trials Products | 2 |
Phase III Trials Products | 1 |
When was vTv Therapeutics founded?
vTv Therapeutics was founded in 1998.
Who are vTv Therapeutics key executives?
vTv Therapeutics's key executives are Carmen Valcarce.
How many employees does vTv Therapeutics have?
vTv Therapeutics has 26 employees.
What is vTv Therapeutics revenue?
Latest vTv Therapeutics annual revenue is $2.8 m.
What is vTv Therapeutics revenue per employee?
Latest vTv Therapeutics revenue per employee is $106.3 k.
Who are vTv Therapeutics competitors?
Competitors of vTv Therapeutics include NGM Biopharmaceuticals, Aimmune Therapeutics and Ampio Pharmaceuticals.
Where is vTv Therapeutics headquarters?
vTv Therapeutics headquarters is located at 3980 Premier Dr #310, High Point.
Where are vTv Therapeutics offices?
vTv Therapeutics has an office in High Point.
How many offices does vTv Therapeutics have?
vTv Therapeutics has 2 offices.
Receive alerts for 300+ data fields across thousands of companies